Search Results
Jun 25, 2025, 12:49 ET Samsung presenta innovaciones en IA para pantallas, barras de sonido y monitores en el 2025 LATAM Visual Display Seminar
certificada por TÜV Rheinland certificada por TÜV Rheinland, otorgada por cumplir con los estándares internacionales para una pantalla de puntos cuánticos (QD) auténtica. Esta certificación TÜV subraya el liderazgo de Samsung en la fabricación de paneles con una pureza de color, un brillo y un rendimiento duradero
More news about: Samsung Mexico
Jun 24, 2025, 06:30 ET Nuvalent Announces Positive Pivotal Data from ARROS-1 Clinical Trial of Zidesamtinib for TKI Pre-treated Patients with Advanced ROS1-positive NSCLC
trial for patients with advanced ROS1-positive NSCLC and other solid tumors. The recommended phase 2 dose (RP2D) for zidesamtinib of 100 mg once daily (QD) was determined during the Phase 1 dose-escalation portion of the trial. The ongoing global, single arm, multi-cohort, open label Phase 2 portion is
More news about: Nuvalent, Inc.
Jun 13, 2025, 09:00 ET Regor to Present Data on its Lead Obesity Candidate, RGT-075, at the 85th Scientific Sessions of American Diabetes Association (ADA)
with weight-related comorbidities. The trial has enrolled approximately 240 participants. All participants on RGT-075 will be given RGT-075 once daily (QD) titrated up over 12 weeks. The primary endpoint is percent change in body weight from baseline to week 36. Secondary endpoints include safety and tolerability
More news about: Regor Therapeutics
Jun 13, 2025, 06:02 ET Enliven Therapeutics Announces Updated Positive Data from Phase 1 Clinical Trial of ELVN-001 in CML at EHA 2025 Congress
April 28, 2025, 90 patients have been enrolled in the ongoing Phase 1 trial across dose levels ranging from 10 mg once a day (QD) to 80 mg twice a day (BID).The vast majority of patients (80%) remain on study with a median treatment duration of ~29 weeks.Patients
More news about: Enliven Therapeutics, Inc.